Key Insights

Highlights

Success Rate

86% trial completion

Published Results

123 trials with published results (10%)

Research Maturity

523 completed trials (41% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

6.6%

84 terminated out of 1274 trials

Success Rate

86.2%

-0.3% vs benchmark

Late-Stage Pipeline

10%

127 trials in Phase 3/4

Results Transparency

24%

123 of 523 completed with results

Key Signals

123 with results86% success84 terminated

Data Visualizations

Phase Distribution

982Total
Not Applicable (404)
Early P 1 (8)
P 1 (196)
P 2 (247)
P 3 (99)
P 4 (28)

Trial Status

Completed523
Unknown245
Recruiting239
Terminated84
Active Not Recruiting72
Not Yet Recruiting66

Trial Success Rate

86.2%

Benchmark: 86.5%

Based on 523 completed trials

Clinical Trials (1274)

Showing 20 of 20 trials
NCT06239194Phase 1Recruiting

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

NCT06266338Phase 2Recruiting

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

NCT05544084Not ApplicableRecruitingPrimary

Adaptation and Implementation of a Patient Navigation Program for Cervical Cancer Screening Across Contexts in Senegal

NCT05799274Phase 1Recruiting

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors

NCT07218003Phase 1Enrolling By Invitation

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

NCT07557225Not ApplicableNot Yet Recruiting

18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors

NCT06459180Phase 3RecruitingPrimary

A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)

NCT07216703Phase 3RecruitingPrimary

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

NCT07124000Recruiting

DESTINY-PANTUMOUR04

NCT05283330Phase 1RecruitingPrimary

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

NCT07547267Not ApplicableCompletedPrimary

The Effect of Vaginal Dilator Use

NCT06814496Phase 1Recruiting

Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

NCT04185389CompletedPrimary

Long-Term Follow-Up of HPV FOCAL Participants

NCT04242823Not ApplicableActive Not RecruitingPrimary

Primary HPV-based Cervical Cancer Screening Algorithms in Botswana

NCT04716127Not ApplicableCompletedPrimary

A Proximity-incentive Strategy for Cervical Cancer Screening

NCT07453459Not ApplicableRecruitingPrimary

Feasibility of HPV Self-Collection Kits for Cervical Cancer Screening

NCT07447895Not ApplicableRecruitingPrimary

Early Pelvic Floor Physical Therapy for Women Undergoing Pelvic Radiation for Gynecologic Malignancies

NCT06157151Phase 2RecruitingPrimary

PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer

NCT03970083Active Not Recruiting

A Pilot Study of Quantitative Tumor Oxygen Measurements in Cervical Cancer

NCT06769152Phase 2RecruitingPrimary

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors

Scroll to load more

Research Network

Activity Timeline